Skip to main navigation Skip to search Skip to main content

Initial ribociclib plus endocrine therapy for HR+/HER2− advanced breast cancer in pre- and postmenopausal Chinese women: Primary results from a phase 2 randomized study

  • Zhimin Shao
  • , Zhongsheng Tong
  • , Qiang Liu
  • , Wei Li
  • , Li Cai
  • , Kunwei Shen
  • , Huiping Li
  • , Chuan Wang
  • , Jin Yang
  • , Zhenchuan Song
  • , Shui Wang
  • , Ting Luo
  • , Wenhe Zhao
  • , Haibo Wang
  • , Yueyin Pan
  • , Jianyun Nie
  • , Xiaohua Zeng
  • , Yanqing Bai
  • , Wendy Chiang
  • , Valeria Guarnaccia
  • Yu Bi, Binghe Xu
  • Fudan University
  • Tianjin Medical University
  • Sun Yat-Sen University
  • Jilin University
  • Harbin Medical University
  • Shanghai Jiao Tong University
  • Peking University
  • Fujian Medical University
  • The First Affiliated Hospital of Xi’an Jiaotong University
  • Hebei Medical University
  • Jiang Su Province RenMin Hospital
  • Sichuan University
  • Sir Run Run Shaw Hospital
  • Qingdao University
  • Anhui Provincial Hospital
  • Yunnan Provincial Cancer Hospital
  • Chongqing University Cancer Hospital
  • Novartis Global Drug Development
  • Novartis
  • Chinese Academy of Medical Sciences

Research output: Contribution to journalArticlepeer-review

4 Scopus citations
Original languageEnglish
Article numbere7408
JournalCancer Medicine
Volume13
Issue number15
DOIs
StatePublished - Aug 2024
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Cite this